Tumor-infiltrating lymphocyte subsets and tertiary lymphoid structures in pulmonary metastases from colorectal cancer - PubMed
Tumor-infiltrating lymphocyte subsets and tertiary lymphoid structures in pulmonary metastases from colorectal cancer
Thomas Schweiger et al. Clin Exp Metastasis. 2016 Oct.
Abstract
The presence of tumor-infiltrating lymphocytes (TILs) and tertiary lymphoid structures (TLSs) reflects an active inflammatory tumor microenvironment. High density of TILs as well as presence of TLS is associated with improved survival in various solid cancer types. We aimed to describe the density and distribution of TILs and TLS in pulmonary metastases (PMs) from primary colorectal cancer (CRC) and its correlation with clinicopathological variables. Fifty-seven CRC pulmonary metastasectomy specimen (PM) and 31 matched primary CRC specimen were included. Cluster of differentiation (CD)3+, CD8+, CD45RO+ and FoxP3+ TILs were evaluated by immunohistochemistry and density was scored semiquantitatively. TLS were evaluated based on morphological criteria. Survival time was defined from pulmonary metastasectomy to death or last follow up. A marked infiltration with CD3+, CD8+, CD45RO+ and FoxP3+ TILs was evident in CRC PM and matched primary CRC. Further assessment of the immune infiltrate in PM showed that a high density of FOXP3+ TILs at the invasive margin [HR 2.40 (1.11-6.96); P = 0.031] and low density of CD8+ cells in TLS [HR 0.30 (0.14-0.79); P = 0.016] were associated with a worse prognosis in univariate analysis. Moreover, a low CD8/FoxP3-ratio of TILs at the invasive margin (P = 0.042) and in TLS (P = 0.027) conferred an impaired prognosis after pulmonary metastasectomy. Our findings suggest that CRC PM harbor an immune active microenvironment. The balance of CD8+ and FoxP3+ T-cells at the tumor border and in TLS provides prognostic information in patients with CRC PM.
Keywords: Colorectal cancer; Pulmonary metastasis; TILs; Tertiary lymphoid structures; Tumor-infiltrating lymphocytes.
Figures

Representative images of high densities of a CD3+, b CD8+, c CD45RO+ and d FoxP3+ TILs (DAB; brown) in pulmonary metastases. e CD3+ tertiary lymphoid structure at the invasive margin between tumor cells and lung parenchyma (magnification ×200/400). (Color figure online)

Kaplan–Meier estimates regarding recurrence-free survival and overall survival of pulmonary metastases dependent on the density of CD8+ and FoxP3+ TILs. Additionally the outcome for the CD8/FoxP3-ratio was calculated

Kaplan–Meier estimates regarding recurrence-free survival and overall survival of pulmonary metastases dependent on the density of CD8+ and FoxP3+ cells in TLS. Additionally the outcome for the CD8/FoxP3-ratio was calculated
Similar articles
-
Shibutani M, Maeda K, Nagahara H, Fukuoka T, Nakao S, Matsutani S, Hirakawa K, Ohira M. Shibutani M, et al. Anticancer Res. 2017 Aug;37(8):4165-4172. doi: 10.21873/anticanres.11804. Anticancer Res. 2017. PMID: 28739701
-
Goc J, Germain C, Vo-Bourgais TK, Lupo A, Klein C, Knockaert S, de Chaisemartin L, Ouakrim H, Becht E, Alifano M, Validire P, Remark R, Hammond SA, Cremer I, Damotte D, Fridman WH, Sautès-Fridman C, Dieu-Nosjean MC. Goc J, et al. Cancer Res. 2014 Feb 1;74(3):705-15. doi: 10.1158/0008-5472.CAN-13-1342. Epub 2013 Dec 23. Cancer Res. 2014. PMID: 24366885
-
Shibutani M, Maeda K, Nagahara H, Fukuoka T, Matsutani S, Kashiwagi S, Tanaka H, Hirakawa K, Ohira M. Shibutani M, et al. BMC Cancer. 2018 Apr 3;18(1):371. doi: 10.1186/s12885-018-4276-y. BMC Cancer. 2018. PMID: 29614981 Free PMC article.
-
Maoz A, Dennis M, Greenson JK. Maoz A, et al. Front Immunol. 2019 Aug 22;10:1884. doi: 10.3389/fimmu.2019.01884. eCollection 2019. Front Immunol. 2019. PMID: 31507584 Free PMC article. Review.
-
Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, Giovannucci E, Dranoff G, Fuchs CS, Ogino S. Nosho K, et al. J Pathol. 2010 Dec;222(4):350-66. doi: 10.1002/path.2774. J Pathol. 2010. PMID: 20927778 Free PMC article. Review.
Cited by
-
Li Q, Zhang D, He W, Chen T, Yan Z, Gao X, Chen L, Zheng X, Xu B, Lu B, Jiang J. Li Q, et al. Oncol Lett. 2020 Sep;20(3):2655-2664. doi: 10.3892/ol.2020.11828. Epub 2020 Jul 8. Oncol Lett. 2020. PMID: 32782582 Free PMC article.
-
Rossi A, Belmonte B, Carnevale S, Liotti A, De Rosa V, Jaillon S, Piconese S, Tripodo C. Rossi A, et al. Front Cell Dev Biol. 2022 Jul 8;10:933113. doi: 10.3389/fcell.2022.933113. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35874810 Free PMC article. Review.
-
Yu A, Fan Z, Ma L, Tang J, Liu W, Han Z, Wang H. Yu A, et al. Immun Inflamm Dis. 2024 Sep;12(9):e70003. doi: 10.1002/iid3.70003. Immun Inflamm Dis. 2024. PMID: 39259184 Free PMC article.
-
Groen-van Schooten TS, Franco Fernandez R, van Grieken NCT, Bos EN, Seidel J, Saris J, Martínez-Ciarpaglini C, Fleitas TC, Thommen DS, de Gruijl TD, Grootjans J, Derks S. Groen-van Schooten TS, et al. J Immunother Cancer. 2024 Jul 1;12(7):e009243. doi: 10.1136/jitc-2024-009243. J Immunother Cancer. 2024. PMID: 38955417 Free PMC article.
-
Yamakoshi Y, Tanaka H, Sakimura C, Mori T, Deguchi S, Yoshii M, Tamura T, Toyokawa T, Lee S, Muguruma K, Hirakawa K, Ohira M. Yamakoshi Y, et al. Mol Clin Oncol. 2021 Apr;14(4):76. doi: 10.3892/mco.2021.2238. Epub 2021 Feb 23. Mol Clin Oncol. 2021. PMID: 33680464 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous